Trials / Completed
CompletedNCT00453063
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 426 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess the effectiveness of mometasone furoate nasal spay (MFNS) once daily (QD) compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total nasal symptom score and the total ocular symptom score.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mometasone furoate | 50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning |
| DRUG | Placebo | Two sprays in each nostril once daily in the morning |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2007-03-28
- Last updated
- 2022-02-09
- Results posted
- 2010-05-17
Source: ClinicalTrials.gov record NCT00453063. Inclusion in this directory is not an endorsement.